352 related articles for article (PubMed ID: 31635813)
1. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
[TBL] [Abstract][Full Text] [Related]
2. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?
Zhou H; Li L; Yang P; Yang L; Zheng JE; Zhou Y; Han Y
BMC Cancer; 2018 May; 18(1):516. PubMed ID: 29720126
[TBL] [Abstract][Full Text] [Related]
3. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
[TBL] [Abstract][Full Text] [Related]
4.
Fan POL; Leung KT; Chan KYY; Leung AWK; Lam GKS; Chow TTW; Cheng FWT; Yuen LYP; Moriyama T; Yang JJ; Li CK
Pediatr Hematol Oncol; 2022 Apr; 39(3):254-266. PubMed ID: 34665987
[TBL] [Abstract][Full Text] [Related]
5. The effects of
Nghia H; Than HH; Dong CV; Oanh TTK; Truc VTT; Ngan CTT; Ngon HT; Binh NT; Dung PC; Anh Vu H; Xinh PT
Pediatr Hematol Oncol; 2022 Sep; 39(6):561-570. PubMed ID: 35156873
[TBL] [Abstract][Full Text] [Related]
6. Dosage of 6-Mercaptopurine in Relation to Genetic TPMT and ITPA Variants: Toward Individualized Pediatric Acute Lymphoblastic Leukemia Maintenance Treatment.
Kouwenberg TW; van den Bosch BJC; Bierau J; Te Loo DMWM; Coenen MJH; Hagleitner MM
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e94-e97. PubMed ID: 31895215
[TBL] [Abstract][Full Text] [Related]
7. Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia.
Dorababu P; Nagesh N; Linga VG; Gundeti S; Kutala VK; Reddanna P; Digumarti R
Eur J Clin Pharmacol; 2012 Apr; 68(4):379-87. PubMed ID: 22009189
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia.
Khera S; Trehan A; Bhatia P; Singh M; Bansal D; Varma N
Cancer Chemother Pharmacol; 2019 Feb; 83(2):341-348. PubMed ID: 30474703
[TBL] [Abstract][Full Text] [Related]
9. The Effect of
Lee JM; Shim YJ; Kim DH; Jung N; Ha JS
Children (Basel); 2021 Mar; 8(3):. PubMed ID: 33804051
[TBL] [Abstract][Full Text] [Related]
10. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.
Maillard M; Nishii R; Yang W; Hoshitsuki K; Chepyala D; Lee SHR; Nguyen JQ; Relling MV; Crews KR; Leggas M; Singh M; Suang JLY; Yeoh AEJ; Jeha S; Inaba H; Pui CH; Karol SE; Trehan A; Bhatia P; Antillon Klussmann FG; Bhojwani D; Haidar CE; Yang JJ
J Natl Cancer Inst; 2024 May; 116(5):702-710. PubMed ID: 38230823
[TBL] [Abstract][Full Text] [Related]
11. Childhood acute lymphoblastic leukemia mercaptopurine intolerance is associated with NUDT15 variants.
Wang DS; Yu CH; Lin CY; Chang YH; Lin KH; Lin DT; Jou ST; Lu MY; Chang HH; Lin SW; Chen HY; Yang YL
Pediatr Res; 2021 Jan; 89(1):217-222. PubMed ID: 32221476
[TBL] [Abstract][Full Text] [Related]
12. NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine.
Khaeso K; Komvilaisak P; Chainansamit SO; Nakkam N; Suwannaying K; Kuwatjanakul P; Hikino K; Dornsena A; Kanjanawart S; Laoaroon N; Vannaprasaht S; Taketani T; Tassaneeyakul W
Drug Metab Pharmacokinet; 2022 Apr; 43():100436. PubMed ID: 35016134
[TBL] [Abstract][Full Text] [Related]
13.
Moradveisi B; Muwakkit S; Zamani F; Ghaderi E; Mohammadi E; Zgheib NK
Front Pharmacol; 2019; 10():916. PubMed ID: 31507415
[No Abstract] [Full Text] [Related]
14. Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia.
Chikondowa P; Munkombwe D; Chikwambi Z; Kuona P; Masimirembwa C
Pharmacogenomics; 2023 Jun; 24(8):449-457. PubMed ID: 37248698
[TBL] [Abstract][Full Text] [Related]
15. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
16.
Puangpetch A; Tiyasirichokchai R; Pakakasama S; Wiwattanakul S; Anurathapan U; Hongeng S; Sukasem C
Pharmacogenomics; 2020 Apr; 21(6):403-410. PubMed ID: 32308129
[No Abstract] [Full Text] [Related]
17. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia.
Buaboonnam J; Sripatanatadasakul P; Treesucon A; Glomglao W; Siraprapapat P; Narkbunnam N; Vathana N; Takpradit C; Phuakpet K; Pongtanakul B; Tongsai S; Sinlapamongkolkul P; Sanpakit K
Pediatr Int; 2019 Aug; 61(8):754-758. PubMed ID: 31166660
[TBL] [Abstract][Full Text] [Related]
18. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
Wan Rosalina WR; Teh LK; Mohamad N; Nasir A; Yusoff R; Baba AA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):237-41. PubMed ID: 21545474
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.
Stocco G; Crews KR; Evans WE
Expert Opin Drug Saf; 2010 Jan; 9(1):23-37. PubMed ID: 20021291
[TBL] [Abstract][Full Text] [Related]
20. [Effect of genetic polymorphism of TPMT and NUDT15 on the tolerance of 6-mercaptopurine therapy in adult acute lymphoblastic leukemia].
Hao QS; Wang Z; Fang QY; Gong XY; Liu KQ; Li Y; Wei H; Wang Y; Li QH; Wang M; Tian Z; Wang JX; Mi YC
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):911-916. PubMed ID: 35045652
[No Abstract] [Full Text] [Related]
[Next] [New Search]
